Tag Archives: AMGN

Top 5 Biotech Stocks To Invest In Right Now

Newlan’s Truism: An “acceptable” level of unemployment means that the government economist to whom it is acceptable still has a job.

I get asked quite a bit this time of year of what my favorite growth play among large cap concerns in the biotech sector is for the year ahead. One name continues to stand out. It is a name not surprisingly that is showing up in the top large cap picks list within biotech for 2017 at such places as Merrill Lynch and RBC Capital.

Celgene (NASDAQ:CELG) should be known to just about every biotech investor. I can think of no other large cap industry player that has a clearer earnings growth trajectory over the next 3-5 years. Celgene is not going to be “home run” investment, but I expect it to continue to deliver “singles” every year with an occasional “double” in some years.

Click to enlarge

Top 5 Biotech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Sean Williams]

    Of course, my “bet against all Alzheimer’s drugs” thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Shannon Jones]

    In this week’s episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte’s Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis’ (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB) might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.

Top 5 Biotech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

  • [By Brian Orelli]

    Earlier this week, Dicerna released promising interim phase I data for its lead drug, DCR-PHXC, in patients with primary hyperoxaluria type 1 and type 2. The company plans to start a trial to be used to support an FDA approval in the first quarter of 2019, but that’ll put it behind Alnylam Pharmaceuticals (NASDAQ:ALNY), which is about to start a phase 3 study testing its drug, lumasiran, in patients with primary hyperoxaluria type 1. Hopefully, Dicerna can use some of its new capital to help accelerate enrollment in its trial to try to catch up to Alnylam.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

Top 5 Biotech Stocks To Invest In Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Biotech Stocks To Invest In Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    If you’re looking to invest in successful big biotechs, two of the biggest are Amgen (NASDAQ:AMGN) and Celgene (NASDAQ:CELG). Over the past 10 years, both stocks have more than tripled.  

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

  • [By ]

    Amgen (Nasdaq: AMGN) — Amgen is a leading global biotech developer with a diverse product portfolio and promising development pipeline. The company has special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel, used primarily for rheumatoid arthritis, which is in the top-five worldwide with annual sales of nearly $8 billion.

Top Biotech Stocks To Buy Right Now

In the first entry of this recently rebooted series, we took a look at top ideas from Consonance Capital (whose performance almost tripled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or Seeking Alpha PRO.

Going forward, I hope to continue delve into the portfolios of successful hedge funds predominantly in the biotech sector, trying to place ourselves in the mindset of the managers and analysts. We do so humbly, knowing that we don’t have access to their research or thought processes (and keeping in mind that positions are constantly changing) – nevertheless, it is an interesting exercise that I hope readers find useful.

Today’s Fund: Deerfield Management Company L.P.

Founded: In 1994

Manager: James E. Flynn

Relevant Reading Material: Prior newsletters/Special report at Fierce Biotech

Market Value: $2.54 billion

Top 10 Holdings %: 33.90% (per Whale Wisdom)

Top Biotech Stocks To Buy Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) ranks No. 1 among all biotech stocks when it comes to market cap. It’s one of the most profitable biotechs and claims one of the largest cash stockpiles in the industry.

  • [By Stephan Byrd]

    PNC Financial Services Group Inc. trimmed its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,120,853 shares of the medical research company’s stock after selling 6,484 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Amgen were worth $391,489,000 as of its most recent SEC filing.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It’s the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

  • [By Logan Wallace]

    Navellier & Associates Inc lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,176 shares of the medical research company’s stock after purchasing an additional 353 shares during the period. Navellier & Associates Inc’s holdings in Amgen were worth $4,278,000 at the end of the most recent reporting period.

Top Biotech Stocks To Buy Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

Top Biotech Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Money Morning News Team]

    Biogen Inc. (NASDAQ: BIIB) is a Massachusetts-based company that focuses on discovering, developing, manufacturing, and delivering therapies for neurodegenerative and neurological diseases worldwide.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already. 

  • [By Trey Thoelcke]

    Biogen Inc. (NASDAQ: BIIB) also saw a death cross earlier this month, and the gap between the moving averages is now more than 9% of the share price. The stock was just downgraded by one analyst and another recently anticipated no growth in the share price. The stock is up more than 6% since the beginning of the year. The consensus recommendation remains to buy Biogen shares.

Top Biotech Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Cory Renauer]

    If approved, Tegsedi will run directly into competition with Alnylam’s (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven’t been tested in a head-to-head study, but most analysts expect Alnylam’s drug to gain a much larger share of the limited space than Akcea’s.

Top 5 Biotech Stocks To Buy Right Now

The management of regulatory affairs essentially contributes to the overall success of new drug development – both at early pre-marketing stages and at all times post-marketing. This means that a biotech or pharma company’s regulatory affairs personnel will be heavily involved in all stages of new drug development both prior to and after an FDA approval. 

That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for inflammatory bowel disease while eliminating or reducing drug psychoactivity.

Top 5 Biotech Stocks To Buy Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Maxx Chatsko]

    Shares of ArQule (NASDAQ:ARQL) rose over 70% today after the company reported full-year 2018 operating results and provided full-year 2019 guidance. That said, investors are probably used to wild swings in the stock price by now. The development-stage pharma didn’t turn in a particularly impressive performance last year. Management expects revenue to drop significantly in the year ahead as collaboration revenue dries up, which will also widen operating losses.

Top 5 Biotech Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Biogen Inc. (NASDAQ: BIIB) is a Massachusetts-based company that focuses on discovering, developing, manufacturing, and delivering therapies for neurodegenerative and neurological diseases worldwide.

  • [By Chris Lange]

    Nightstar Therapeutics PLC (NASDAQ: NITE) shares exploded early on Monday after it was announced that the firm would be acquired by Biogen Inc. (NASDAQ: BIIB). The transaction is expected to close by mid-year 2019.

  • [By Garrett Baldwin]

    Nike Inc. (NYSE: NKE) will lead a busy day of earnings reports. The firm expects that its year-over-year sales will have increased by 7%. The company’s stock slumped in February after Duke basketball player Zion Williamson was hurt blowing out his sneaker in the first minute of a major contest against North Carolina. Expect analysts to ask a lot of questions about Nike’s expectations for global economic growth and its exposure to a weakening Chinese economy.
    Stocks to Watch Today: BIIB, BA, LEVI
    Shares of Biogen Inc. (NASDAQ: BIIB) plunged more than 25% after the company announced a major setback for a key Alzheimer’s drug. The biotech giant announced that its experimental drug “aducanumab” is unlikely to be effective for mass deployment and that it will halt its research. One analyst described this as a “transformative failure for Biogen’s pipeline.” This is a massive setback for one of the top biotech companies in the world. Shares of Boeing Co. (NYSE: BA) are off again Thursday on news that the investigation into its 737 Max jets has expanded. According to reports, the FBI has now joined a federal investigation into the certification process for the jet. The Department of Transportation launched an audit of the Federal Aviation Administration’s approval of the jet, which received certification two years ago. Boeing and the FAA have faced global scrutiny over two fatal crashes involving the 737 Max jet series and news of previous pilot complaints about the planes. Levi Strauss & Co. (NYSE: LEVI) will return to the public markets for the first time in 34 years. The iconic apparel company will launch its IPO today with a price of $17 per share. That would set the company’s market capitalization at $6.6 billion. Look for other earnings reports from Canadian Solar Inc. (NASDAQ: CSIQ), Cintas Corp. (NASDAQ: CTAS), CNOOC Ltd. (NYSE: CEO), Conagra Brands Inc. (NYSE: CAG), Darden Restaurants Inc. (NYSE: DRI), and Lands’ End Inc. (NYSE: LE).
    Public Law 92-

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    As noted, the ability to take numerous swings for the fence makes Ionis special. It’s often a marvel when a mid-cap drugmaker has a half-dozen experimental drugs, let alone one working with 25. Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ:BIIB), is one such drug that’s put Ionis and its antisense technology on the map. Last year, Spinraza netted “just” $882 million in total sales, but delivered $364 million globally in the first quarter of 2018. That extrapolates out to more than $1.4 billion, which means added royalty revenue for Ionis.

  • [By Todd Campbell]

    Unfortunately for investors, June’s discovery wasn’t exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo’s hemophilia program.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.33 million shares from the previous 3.86 million. The stock recently traded at $306.68 within a 52-week range of $249.17 to $370.57.

Top 5 Biotech Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday.

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Cory Renauer]

    Taking a medical breakthrough from concept through commercial success is like ascending a mountain that grows taller and more treacherous with every setback. It’s taken Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) 16 years to launch its first drug, so challenges have had plenty of time to take up positions along this company’s path to a successful first launch.

Top 5 Biotech Stocks To Buy Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Investors are beginning to wonder if bluebird bio is at risk of losing market share before it really even begins life as a commercial company. The latest example: In September Amgen (NASDAQ:AMGN) released promising preliminary data from a small ongoing phase 1 trial, investigating a new immunotherapy as a potential treatment for advanced multiple myeloma. While the initial data release included just five patients, all had failed to respond to between four and six previous treatments. Amgen’s drug, AMG-420, a “simpler” immunotherapy compared to the cellular therapies being developed by bluebird bio and Celgene, resulted in a complete remission in four of them. That’s very impressive.

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD), Amgen (NASDAQ:AMGN), and Johnson & Johnson (NYSE:JNJ) rank as the three top biopharmaceutical companies when it comes to cash stockpiles. Here’s what these drugmakers are most likely to do with all that money — and whether or not you should consider investing some of your hard-earned cash to buy their stocks.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Amgen (AMGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    In other news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the transaction, the director now owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,777 shares of company stock valued at $4,648,718. Insiders own 0.27% of the company’s stock.

    COPYRIGHT VIOLATION WARNING: “Boston Financial Mangement LLC Has $3.86 Million Stake in Amgen, Inc. (AMGN)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at www.tickerreport.com/banking-finance/4162787/boston-financial-mangement-llc-has-3-86-million-stake-in-amgen-inc-amgn.html.

    Amgen Profile

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest drop to 9.87 million shares from the previous level of 10.18 million. Shares were last seen trading at $185.79, in a 52-week range of $163.31 to $210.19.

Best Performing Stocks To Own For 2019

On Tuesday, e-commerce platform Shopify (NYSE:SHOP) closed the books on a big year. Merchant and subscription solutions revenue on its platform soared as sellers flocked to Shopify. This led to a nice jump in revenue and gross profit during the year. Unsurprisingly, the stock rose sharply, too: Shares gained nearly 30% over the past 12 months, handily outperforming the S&P 500’s 3% gain over the same time period.

If the stock’s outperformance over the past 12 months has caught your attention and you’re looking for more insight into what’s driving the company’s stellar results, look no further. Here are the eight most important metrics behind Shopify’s staggering growth recently.

Shopify platform. Image source: Shopify.

1. Gross merchandise volume jumped 56%

Shopify’s gross merchandise volume (GMV) in 2018 rose an impressive 56% year over year, to $16.6 billion. While this is a deceleration from Shopify’s 71% year-over-year growth in 2017 GMV, it’s still impressively steep.

Best Performing Stocks To Own For 2019: Media General, Inc.(MEG)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Macquarie upgraded shares of MEG Energy (TSE:MEG) from a neutral rating to an outperform rating in a research note released on Monday morning. Macquarie currently has C$12.50 price objective on the stock, up from their prior price objective of C$8.00.

  • [By Ethan Ryder]

    MEG Energy (TSE:MEG) Director William Robert Klesse sold 4,783 shares of the company’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of C$8.78, for a total transaction of C$41,994.74.

  • [By Logan Wallace]

    MEG Energy (TSE:MEG)‘s stock had its “sector perform spec overwgt” rating reissued by analysts at National Bank Financial in a research report issued on Tuesday.

Best Performing Stocks To Own For 2019: First Internet Bancorp(INBK)

Advisors’ Opinion:

  • [By Logan Wallace]

    Media coverage about First Internet Bancorp (NASDAQ:INBK) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. First Internet Bancorp earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media headlines about the bank an impact score of 45.3072144341855 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Max Byerly]

    Penn Capital Management Co. Inc. lowered its stake in First Internet Bancorp (NASDAQ:INBK) by 22.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,312 shares of the bank’s stock after selling 24,888 shares during the period. Penn Capital Management Co. Inc.’s holdings in First Internet Bancorp were worth $3,231,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Craig Hallum began coverage on shares of First Internet Bancorp (NASDAQ:INBK). They issued a buy rating and a $50.00 target price on the stock.

    Intuit (NASDAQ:INTU) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $213.00 price target on the stock. According to Zacks, “We are optimistic on Intuit’s growing SMB exposure and believe that its strategic acquisitions will fortify this segment. Due to the continuously emerging new technologies and current market trends, cloud-based business and financial software solutions have been gaining momentum. As Intuit is already a market leader in this segment, the increased adoption helped it gain new customers, in turn, boosting the overall performance. Estimates have been stable for Intuit of late. Moreover, the company’s strategy of shifting its business to cloud-based subscription model will help generate more stable revenues over the long run. Intuit’s shares have outperformed the industry in a year’s time.”

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on First Internet Bancorp (INBK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    First Internet Bancorp (NASDAQ:INBK) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Wednesday.

  • [By Rich Smith]

    The year was 1999 and “internet” stocks were all the rage. On opposite sides of the country, two banks — BofI Holding (NASDAQ:BOFI) and First Internet Bancorp (NASDAQ:INBK) — were both betting on a business model of asset-light internet banking. Nearly two decades later, one of these banks has grown into a $2.6 billion force to be contended with, while the other lags behind with a market cap of less than $350 million.

Best Performing Stocks To Own For 2019: Immersion Corporation(IMMR)

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Immersion Corp  (NASDAQ:IMMR)Q4 2018 Earnings Conference CallFeb. 26, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Here are some of the news headlines that may have impacted Accern’s analysis:

    Get Immersion alerts:

    Turtle Beach (HEAR) and Immersion (IMMR) Are Aggressive Growth Stocks (finance.yahoo.com) Immersion (IMMR) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com) Is the Options Market Predicting a Spike in Immersion (IMMR) Stock? (zacks.com) Immersion (IMMR) vs. Radisys (RSYS) Head-To-Head Review (americanbankingnews.com) Stock Traders Purchase High Volume of Immersion Put Options (IMMR) (americanbankingnews.com)

    Immersion opened at $13.76 on Friday, according to Marketbeat. Immersion has a 12 month low of $13.32 and a 12 month high of $13.55. The firm has a market cap of $422.28 million, a P/E ratio of -11.56, a P/E/G ratio of 0.53 and a beta of 1.22.

  • [By Lisa Levin] Gainers
    The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results.
    MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results.
    ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million.
    Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results.
    Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results.
    VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71.
    Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results.
    Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results.
    Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739.
    Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69
  • [By Logan Wallace]

    Immersion Co. (NASDAQ:IMMR) shares reached a new 52-week high and low on Tuesday . The company traded as low as $15.49 and last traded at $15.44, with a volume of 45044 shares trading hands. The stock had previously closed at $15.11.

Best Performing Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Campbell]

    Complex biologic medications that are made in living cells are some of the most expensive drugs on the market, but expiring patents on biologics are putting $100 billion in sales up for grabs by 2020, according to GBI Research. Stealing market share away from costly biologics as they lose patent protection got companies, including Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN) and Mylan (NASDAQ:MYL) betting big bucks on biosimilars that work similarly, and a new Trump administration proposal this past week could boost biosimilar sales significantly in the future.

  • [By Stephan Byrd]

    Cpwm LLC increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 59.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,702 shares of the medical research company’s stock after purchasing an additional 3,253 shares during the period. Cpwm LLC’s holdings in Amgen were worth $1,606,000 at the end of the most recent quarter.

  • [By Keith Speights]

    The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.

  • [By Logan Wallace]

    Cantor Fitzgerald set a $223.00 price target on Amgen (NASDAQ:AMGN) in a research report sent to investors on Monday. The firm currently has a neutral rating on the medical research company’s stock.

Top 10 Biotech Stocks To Invest In 2019

Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.

It was a bumpy ride for shareholders, though. Corbus stock had some big drops along the way, most recently falling around 25% before clawing its way back. How high can Corbus stock go from here?

Image source: Getty Images.

The main story for Corbus

There’s one driving factor behind Corbus’ success thus far: JBT-101 (also known as resunab). The novel synthetic oral endocannabinoid-mimetic drug is being evaluated in four clinical studies.

Corbus announced positive results in November from a phase 2 study of JBT-101 in treating systemic sclerosis, a chronic autoimmune rheumatic disease. Patients receiving the experimental drug achieved a median Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score of 33% at week 16 of treatment. Patients in the placebo group scored 0%. CRISS scores above 20% are considered to be meaningful improvement.

Top 10 Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Top 10 Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    In other news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the transaction, the director now owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,777 shares of company stock valued at $4,648,718. Insiders own 0.27% of the company’s stock.

    COPYRIGHT VIOLATION WARNING: “Boston Financial Mangement LLC Has $3.86 Million Stake in Amgen, Inc. (AMGN)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at www.tickerreport.com/banking-finance/4162787/boston-financial-mangement-llc-has-3-86-million-stake-in-amgen-inc-amgn.html.

    Amgen Profile

  • [By Keith Speights]

    The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.

  • [By ]

    For example, if you buy 100 shares of the Nasdaq 100 ETF (NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares of Amgen (NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest drop to 9.87 million shares from the previous level of 10.18 million. Shares were last seen trading at $185.79, in a 52-week range of $163.31 to $210.19.

  • [By Max Byerly]

    Hammer Asset Management LLC purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,988 shares of the medical research company’s stock, valued at approximately $3,136,000. Amgen makes up 2.7% of Hammer Asset Management LLC’s holdings, making the stock its 13th largest holding.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.

Top 10 Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Here are some of the news stories that may have effected Accern’s analysis:

    Get Biogen alerts:

    Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion (americanbankingnews.com) Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer? (finance.yahoo.com) 5 Trade Ideas For Monday: AMTD, BIIB, DEO, FITB, TECK (investing.com) $5.29 EPS Expected for Biogen (BIIB) This Quarter (americanbankingnews.com) Biogen (BIIB) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)

    Shares of Biogen traded up $5.45, reaching $281.51, during midday trading on Wednesday, according to MarketBeat Ratings. 1,514,169 shares of the company’s stock were exchanged, compared to its average volume of 1,729,786. Biogen has a 52-week low of $276.94 and a 52-week high of $281.57. The firm has a market cap of $59.58 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 1.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 3.23.

  • [By Brian Orelli]

    Likewise, Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS), which have the only SMA drug on the market, are feeling the heat from the promising data with shares down 5.6% and 7.3%, respectively.

  • [By Lisa Levin] Companies Reporting Before The Bell
    United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
    The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
    Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
    Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
    Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
    The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
    Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
    3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
    JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
    Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
    Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
    Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
    Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
    The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
    Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
    PACCAR Inc (NASDAQ: PCAR) is projected to
  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings report from partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was released for IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

  • [By Brian Feroldi]

    Data source: Alkermes. GAAP = generally accepted accounting principles.

    What happened with Alkermes this quarter?
    Sales of Alkermes’ opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company’s schizophrenia drug Aristada rose 62% to $29.2 million. Manufacturing and royalty revenue related to Johnson & Johnson’s schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related to Acorda Therapeutics’ multiple sclerosis drug fell 3% to $28.3 million. Research and development revenue earned as part of its collaboration with Biogen (NASDAQ:BIIB) for BIIB098 — which used to be called ALKS 8700 — was $17.5 million.

    Looking beyond the financials, here’s an overview of the key events from the period:

Top 10 Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Brian Orelli]

    Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) were up 19% at 12:04 p.m. EDT on Monday after rival Pfizer (NYSE:PFE) released data for its transthyretin amyloid (ATTR) drug tafamidis at the ESC Congress 2018, which were also published in the New England Journal of Medicine. Earlier this month, Alnylam got its ATTR drug, Onpattro, approved by the Food and Drug Administration. Shares of Ionis Pharmaceuticals (NASDAQ:IONS) and Akcea Therapeutics (NASDAQ:AKCA), which are jointly developing another ATTR drug, Tegsedi, are up 10% and 2.6% respectively.

Top 10 Biotech Stocks To Own Right Now

Financial Gravity Companies Inc. raised its stake in shares of Grifols (NASDAQ:GRFS) by 264.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,862 shares of the biotechnology company’s stock after purchasing an additional 10,054 shares during the quarter. Financial Gravity Companies Inc.’s holdings in Grifols were worth $282,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of GRFS. Dean Capital Investments Management LLC bought a new position in shares of Grifols during the 4th quarter worth about $214,000. Pitcairn Co. bought a new stake in Grifols in the fourth quarter valued at about $228,000. Lenox Wealth Management Inc. increased its stake in Grifols by 93.2% in the fourth quarter. Lenox Wealth Management Inc. now owns 11,460 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 5,529 shares during the period. Commerce Bank bought a new stake in Grifols in the first quarter valued at about $313,000. Finally, Dowling & Yahnke LLC bought a new stake in Grifols in the fourth quarter valued at about $327,000. Institutional investors own 22.35% of the company’s stock.

Top 10 Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Pfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

Top 10 Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Brian Orelli]

    Data source: Ionis Pharmaceuticals.

    What happened with Ionis Pharmaceuticals this quarter?
    Royalties from Biogen (NASDAQ:BIIB) for sales of Spinraza came in at $57 million, more than double the year-ago quarter. The rest of the revenue comes from research and development revenue, which can vary from quarter to quarter due to milestone payments. In July, Ionis’ marketing partner Akcea Therapeutics (NASDAQ:AKCA) received EU approval for Tegsedi, the brand name for inotersen that treats hereditary transthyretin amyloidosis (ATTR). Earlier this month, Akcea licensed the Latin American rights to Tegsedi and Waylivra, which treats diseases with high lipid levels, to PTC Therapeutics (NASDAQ:PTCT); Ionis gets 60% of the milestone and royalty payments from PTC Therapeutics for Tegsedi and 50% of the payments for Waylivra. The larger loss came from an increase in R&D expenses, as Ionis and Akcea — which is still included in Ionis’ profit-loss statement because Ionis owns a majority stake — continue to advance Ionis’ pipeline. Selling, general, and administrative costs also increased as Akcea prepares to launch Tegsedi and Waylivra. Ionis’ balance sheet can certainly absorb the quarterly loss; the biotech ended the quarter with $2 billion in the bank thanks to its latest deal with Biogen, which is plenty to get by as it waits for revenue to start rolling in.

    Image source: Getty Images.

  • [By Chris Lange]

    Biogen Inc.’s (NASDAQ: BIIB) second-quarter report is scheduled for Tuesday before the markets open. The consensus estimates are $5.24 in earnings per share (EPS) on $3.26 billion in revenue. The shares ended the week trading at $357.56. The consensus price target is $367.08, and the 52-week trading range is $249.17 to $370.57.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Logan Wallace]

    Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, April 24th. The biotechnology company reported $6.05 earnings per share for the quarter, topping the consensus estimate of $5.93 by $0.12. The firm had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. Biogen’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.20 earnings per share. research analysts anticipate that Biogen will post 23.94 earnings per share for the current year.

  • [By Sean Williams]

    Of course, my “bet against all Alzheimer’s drugs” thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.

Top 10 Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Motley Fool Transcribers]

    Arqule Inc  (NASDAQ:ARQL)Q4 2018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Brian Feroldi]

    The study in question is called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

  • [By Trey Thoelcke]

    Amgen Inc.’s (NASDAQ: AMGN) death cross also occurred this week, after the gap between the two averages had been closing since last October. As with some of its peers, short interest in this biotech stock has waned recently. Amgen shares are down more than 4% year to date. Yet, here too analysts recommend buying shares.

  • [By Logan Wallace]

    Navellier & Associates Inc lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,176 shares of the medical research company’s stock after purchasing an additional 353 shares during the period. Navellier & Associates Inc’s holdings in Amgen were worth $4,278,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Philadelphia Trust Co. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,676 shares of the medical research company’s stock after selling 6,501 shares during the quarter. Amgen makes up 1.2% of Philadelphia Trust Co.’s portfolio, making the stock its 22nd biggest position. Philadelphia Trust Co.’s holdings in Amgen were worth $13,784,000 as of its most recent SEC filing.

  • [By Keith Speights]

    The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.

Top 10 Biotech Stocks To Buy For 2019

Millennium Management LLC grew its stake in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 51.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,031 shares of the biotechnology company’s stock after buying an additional 32,362 shares during the quarter. Millennium Management LLC owned about 0.29% of vTv Therapeutics worth $387,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, C WorldWide Group Holding A S acquired a new position in shares of vTv Therapeutics in the 1st quarter worth approximately $399,000. Hedge funds and other institutional investors own 13.42% of the company’s stock.

Get vTv Therapeutics alerts:

Several equities analysts have recently issued reports on VTVT shares. Zacks Investment Research raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research note on Thursday, May 24th. ValuEngine raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. vTv Therapeutics presently has a consensus rating of “Hold” and an average target price of $13.11.

Top 10 Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of large-cap biotech Biogen (NASDAQ:BIIB) gained a healthy 15.2% in July, according to data from S&P Global Market Intelligence. What triggered this breakout? 

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stock’s 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.

  • [By Brian Orelli]

    Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earnings increase in the first quarter. While revenue growth wasn’t as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren’t a sign of future trouble.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stock’s 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

Top 10 Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Alnylam’s (NASDAQ:ALNY) Onpattro is the first Food and Drug Administration (FDA)-approved RNAi therapy. However, competition is fast approaching and could make it difficult for Alnylam to pocket profits. Can Onpattro carve out significant sales as a treatment for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis?

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now.  However,  In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release.”

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

Top 10 Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By ]

    Amgen (Nasdaq: AMGN) — Amgen is a leading global biotech developer with a diverse product portfolio and promising development pipeline. The company has special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel, used primarily for rheumatoid arthritis, which is in the top-five worldwide with annual sales of nearly $8 billion.

  • [By Stephan Byrd]

    Marco Investment Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,601 shares of the medical research company’s stock after buying an additional 5,265 shares during the period. Amgen comprises approximately 3.4% of Marco Investment Management LLC’s portfolio, making the stock its 3rd largest position. Marco Investment Management LLC’s holdings in Amgen were worth $21,893,000 as of its most recent SEC filing.

  • [By Cory Renauer]

    The market for complex therapies that train living cells to attack cancer is taking baby steps, but there’s still a lot of enthusiasm for experimental drugs coming through the pipeline from bluebird bio (NASDAQ:BLUE) and it’s big biotech partner Celgene (NASDAQ:CELG). That enthusiasm fell a notch after Amgen (NASDAQ:AMGN) released exciting data from a handful of patients that suggests it’s found a much easier way to achieve the same goal. 

  • [By Brian Feroldi]

    The study in question is called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Amgen (AMGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is waiting for the FDA to review its Biologics License Application (BLA) for Aimovig (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. The FDA has set a PDUFA date for May 17.

Hot Biotech Stocks To Buy For 2019

U.S. stocks reversed direction to close mostly lower Thursday as weak financials and consumer staples shares eclipsed a rally in the health-care and biotechnology sectors.

The S&P 500
SPX, -0.05%
 dropped 1.11 points to finish at 2,434.50, with financial stocks falling 0.6% and consumer staples shedding 0.7%.

Hot Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.

  • [By Cory Renauer]

    If approved, Tegsedi will run directly into competition with Alnylam’s (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven’t been tested in a head-to-head study, but most analysts expect Alnylam’s drug to gain a much larger share of the limited space than Akcea’s.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Jim Crumly]

    You would think that when a drug company that’s been working for 16 years to develop drugs using a novel therapeutic approach wins its first-ever approval from the U.S. Food and Drug Administration (FDA), confetti would fall from the ceiling and its investors would be celebrating a huge stock gain the next day. That didn’t happen this week for shareholders of Alnylam Pharmaceuticals (NASDAQ:ALNY), with shares dropping 6.6% the day after the announcement, and there were two main reasons for that.

Hot Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.33 million shares from the previous 3.86 million. The stock recently traded at $306.68 within a 52-week range of $249.17 to $370.57.

  • [By Ethan Ryder]

    Russell Investments Group Ltd. boosted its holdings in Biogen (NASDAQ:BIIB) by 40.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 183,809 shares of the biotechnology company’s stock after buying an additional 52,654 shares during the period. Russell Investments Group Ltd.’s holdings in Biogen were worth $50,222,000 as of its most recent SEC filing.

  • [By Chris Lange]

    Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.

Hot Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL)’s share price rose 6.2% during trading on Thursday . The stock traded as high as $5.21 and last traded at $5.15. Approximately 955,706 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 1,244,948 shares. The stock had previously closed at $4.85.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    That difficulty hasn’t stopped market research firm EvaluatePharma from trying, though. EvaluatePharma recently published a list of the drugmakers with the projected highest value creation from pipeline products between 2018 and 2024. Here’s why Novartis (NYSE:NVS), AbbVie (NYSE:ABBV), Celgene (NASDAQ:CELG), AstraZeneca (NYSE:AZN), and Amgen (NASDAQ:AMGN) ranked at the top.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.

  • [By Cory Renauer]

    The market for complex therapies that train living cells to attack cancer is taking baby steps, but there’s still a lot of enthusiasm for experimental drugs coming through the pipeline from bluebird bio (NASDAQ:BLUE) and it’s big biotech partner Celgene (NASDAQ:CELG). That enthusiasm fell a notch after Amgen (NASDAQ:AMGN) released exciting data from a handful of patients that suggests it’s found a much easier way to achieve the same goal. 

Top 5 Biotech Stocks For 2019

What happened

After the company reported second-quarter earnings, shares of Spectrum Pharmaceuticals (NASDAQ:SPPI), a commercial-stage hematology and oncology biotech, jumped 13% as of 11:25 a.m. EDT on Friday.

So what

Here’s a look at the headline numbers from the quarter:

Revenue was $24.1 million. This figure was down 30% from the year-ago period and came up short of the $28 million in revenue that Wall Street had expected. Net income was $13.7 million. However, adjusted net income was a loss of $21.6 million, or $0.21 per share. That figure matched market watchers’ projections. Cash balance at quarter’s end was $270 million, which the company expects will be enough to fund itself in 2020. Management reaffirmed revenue guidance for the full year to land between $95 million to $115 million. 

Image source: Getty Images.

Top 5 Biotech Stocks For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Keith Speights]

    Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ:NITE), Arbutus Biopharma (NASDAQ:ABUS), and Biogen (NASDAQ:BIIB). What caused these stocks to soar, and are they smart picks to buy now? Here’s what you need to know.

  • [By Cory Renauer]

    Biogen Inc. (NASDAQ:BIIB) and Gilead Sciences, Inc. (NASDAQ:GILD) were two of biotech’s best-performing stocks in years past, but investors are a lot more worried about where they’re going right now. Gilead Sciences has a new management team and a new focus on treating cancer. Now that competitors have diminished Biogen’s dominance in the multiple sclerosis space, the company’s taking bold steps as well.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.33 million shares from the previous 3.86 million. The stock recently traded at $306.68 within a 52-week range of $249.17 to $370.57.

  • [By Joseph Griffin]

    Here are some of the news stories that may have effected Accern’s analysis:

    Get Biogen alerts:

    Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion (americanbankingnews.com) Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer? (finance.yahoo.com) 5 Trade Ideas For Monday: AMTD, BIIB, DEO, FITB, TECK (investing.com) $5.29 EPS Expected for Biogen (BIIB) This Quarter (americanbankingnews.com) Biogen (BIIB) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)

    Shares of Biogen traded up $5.45, reaching $281.51, during midday trading on Wednesday, according to MarketBeat Ratings. 1,514,169 shares of the company’s stock were exchanged, compared to its average volume of 1,729,786. Biogen has a 52-week low of $276.94 and a 52-week high of $281.57. The firm has a market cap of $59.58 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 1.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 3.23.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stock’s 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.

Top 5 Biotech Stocks For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

Top 5 Biotech Stocks For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Cpwm LLC increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 59.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,702 shares of the medical research company’s stock after purchasing an additional 3,253 shares during the period. Cpwm LLC’s holdings in Amgen were worth $1,606,000 at the end of the most recent quarter.

  • [By Todd Campbell]

    Amgen (NASDAQ:AMGN) may not be as exciting a stock to own as clinical-stage upstarts, but shares in this biotech Goliath have been mounting a rally lately that should make every investor take notice. So far in 2018, Amgen’s rewarded investors with an 18% return.

  • [By Todd Campbell, Chris Neiger, and Sean Williams]

    Whirlpool Corporation (NYSE:WHR), Amgen Inc. (NASDAQ:AMGN), and Microsoft Corporation (NASDAQ:MSFT) are very different companies, but they all share one thing in common: Our Motley Fool contributors think now’s a good time to add them to dividend portfolios. What makes these companies special? Read on to learn why Whirlpool could be a bargain-bin buy because of tariffs, Amgen could benefit from dividend growth thanks to new drugs, and Microsoft’s big bet on the cloud makes it a savvy buy.

  • [By Shane Hupp]

    Amgen (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by Oppenheimer in a research note issued on Tuesday. They currently have a $224.00 price objective on the medical research company’s stock. Oppenheimer’s price target would indicate a potential upside of 8.26% from the stock’s current price.

  • [By Keith Speights]

    The big reason Humira will maintain its position at the top is the U.S. market. U.S. sales of the drug are projected to be around $12.2 billion in 2024. That’s not much lower than Humira’s 2017 U.S. sales of nearly $12.4 billion. Will Amgen’s (NASDAQ:AMGN) biosimilar Amjevita, which will go on sale in the U.S. effective Jan. 31, 2023, really make that small of a dent in Humira’s sales? Not really. The impact will be greater than the 2024 projections indicate.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Amgen (AMGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Biotech Stocks For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Pfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Cory Renauer]

    If approved, Tegsedi will run directly into competition with Alnylam’s (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven’t been tested in a head-to-head study, but most analysts expect Alnylam’s drug to gain a much larger share of the limited space than Akcea’s.

Hot Biotech Stocks To Own For 2019

Ascendis Pharma A/S (NASDAQ:ASND) – Leerink Swann issued their FY2020 earnings per share estimates for Ascendis Pharma A/S in a research note issued on Wednesday, August 29th. Leerink Swann analyst J. Schwartz expects that the biotechnology company will post earnings of ($5.49) per share for the year. Leerink Swann currently has a “Market Perform” rating and a $70.00 target price on the stock.

Get Ascendis Pharma A/S alerts:

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, May 30th. The biotechnology company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.38). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.30 million. Ascendis Pharma A/S had a negative net margin of 12,089.94% and a negative return on equity of 64.87%.

Hot Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Shane Hupp]

    Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79

  • [By Keith Speights]

    The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.

  • [By Brian Feroldi]

    Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.

  • [By ]

    Amgen (Nasdaq: AMGN) — Amgen is a leading global biotech developer with a diverse product portfolio and promising development pipeline. The company has special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel, used primarily for rheumatoid arthritis, which is in the top-five worldwide with annual sales of nearly $8 billion.

Hot Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already. 

  • [By Dan Caplinger]

    Wall Street continued its downward streak on Monday, with the Dow Jones Industrial Average falling more than 100 points. Most major benchmarks fell more modestly, with a few actually poking into positive territory on the day. Trade-sensitive stocks were among the weakest as investors focused on uncertainty related to tariff disputes between the U.S. and China. But for some other companies, bad news of a different sort was responsible for the drops in their shares. Biogen (NASDAQ:BIIB), Baytex Energy (NYSE:BTE), and Catalyst Biosciences (NASDAQ:CBIO) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Keith Speights]

    Surprising only begins to describe the latest clinical study results announced by Biogen (NASDAQ:BIIB) and its partner, Japanese drugmaker Eisai (NASDAQOTH:ESALY). On July 5, the two companies reported positive topline results from a phase 2 clinical study of experimental Alzheimer’s disease drug BAN2401 at 18 months.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.86 million shares from the previous 3.45 million. The stock recently traded at $287.00, within a 52-week range of $244.28 to $370.57.

  • [By Todd Campbell]

    Drugmakers’ dustbins are filled with failed attempts to slow the progression of Alzheimer’s disease, yet drug developers, including Biogen (NASDAQ:BIIB), remain undaunted in their pursuit of new treatments. Recently, Biogen reported data from a midstage trial that suggests it could be rewarded for its perseverance. In hundreds of patients, the company’s BAN2401 successfully slowed disease progression as measured by the Alzheimer’s Disease Composite Score (ADCOMS). Is this the breakthrough patients have been waiting for?

Hot Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
     Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Hot Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Jim Crumly]

    As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now.  However,  In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release.”

  • [By Stephan Byrd]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday.

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Pfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.